Journal of Viral Hepatitis

Papers
(The H4-Index of Journal of Viral Hepatitis is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Issue Information31
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study31
Issue Information27
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues25
23
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities22
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination22
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B22
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England22
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study21
Issue Information21
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab20
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐1919
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review18
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C17
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine17
Issue Information16
Clinical Observational Study on HBV Reactivation After Direct‐Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China16
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection16
0.1784200668335